image
Healthcare - Medical - Devices - NASDAQ - US
$ 13.92
-0.642 %
$ 197 M
Market Cap
-23.2
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ANIK stock under the worst case scenario is HIDDEN Compared to the current market price of 13.9 USD, Anika Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ANIK stock under the base case scenario is HIDDEN Compared to the current market price of 13.9 USD, Anika Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ANIK stock under the best case scenario is HIDDEN Compared to the current market price of 13.9 USD, Anika Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANIK

image
$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
120 M REVENUE
-28.05%
-5.1 M OPERATING INCOME
94.18%
-56.4 M NET INCOME
31.79%
5.4 M OPERATING CASH FLOW
402.18%
-8.33 M INVESTING CASH FLOW
-53.57%
-12.7 M FINANCING CASH FLOW
-101.28%
-1.29 M REVENUE
-3.33%
27.8 M OPERATING INCOME
199.29%
-21.9 M NET INCOME
26.92%
1.58 M OPERATING CASH FLOW
-68.46%
-1.31 M INVESTING CASH FLOW
28.03%
-5.35 M FINANCING CASH FLOW
-34.15%
Balance Sheet Anika Therapeutics, Inc.
image
Current Assets 114 M
Cash & Short-Term Investments 55.6 M
Receivables 23.6 M
Other Current Assets 34.4 M
Non-Current Assets 89.1 M
Long-Term Investments 0
PP&E 64.7 M
Other Non-Current Assets 24.4 M
27.44 %11.64 %16.98 %31.90 %12.04 %Total Assets$202.7m
Current Liabilities 23.3 M
Accounts Payable 5.62 M
Short-Term Debt 1.92 M
Other Current Liabilities 15.8 M
Non-Current Liabilities 25.4 M
Long-Term Debt 24 M
Other Non-Current Liabilities 1.43 M
11.52 %3.93 %32.35 %49.26 %2.94 %Total Liabilities$48.8m
EFFICIENCY
Earnings Waterfall Anika Therapeutics, Inc.
image
Revenue 120 M
Cost Of Revenue 43.9 M
Gross Profit 76 M
Operating Expenses 81.1 M
Operating Income -5.1 M
Other Expenses 51.3 M
Net Income -56.4 M
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)120m(44m)76m(81m)(5m)(51m)(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.38% GROSS MARGIN
63.38%
-4.25% OPERATING MARGIN
-4.25%
-47.02% NET MARGIN
-47.02%
-36.62% ROE
-36.62%
-27.81% ROA
-27.81%
-8.98% ROIC
-8.98%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Anika Therapeutics, Inc.
image
35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -56.4 M
Depreciation & Amortization 8.12 M
Capital Expenditures -7.73 M
Stock-Based Compensation 13.1 M
Change in Working Capital 0
Others 40.3 M
Free Cash Flow -2.33 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Anika Therapeutics, Inc.
image
ANIK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Anika Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year End Earnings Conference Call. At this time, all lines are in listen-only mode. seekingalpha.com - 1 month ago
Anika Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 1 month ago
Anika Completes Divestiture of Parcus Medical Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio globenewswire.com - 1 month ago
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025 BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. globenewswire.com - 1 month ago
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. globenewswire.com - 1 month ago
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET. Management will also participate in one-on-one investor meetings throughout the event. globenewswire.com - 3 months ago
Anika To Participate in December 2024 Investor Conferences BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences. globenewswire.com - 4 months ago
New Strong Sell Stocks for November 11th AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024. zacks.com - 5 months ago
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development and IR Cheryl Blanchard - President and CEO Steve Griffin - EVP, CFO and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Co. Mike Petusky - Barrington Research Operator Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions]. seekingalpha.com - 5 months ago
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago. zacks.com - 5 months ago
Anika Reports Third Quarter 2024 Financial Results Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds globenewswire.com - 5 months ago
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile globenewswire.com - 5 months ago
8. Profile Summary

Anika Therapeutics, Inc. ANIK

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 197 M
Dividend Yield 0.00%
Description Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Contact 32 Wiggins Avenue, Bedford, MA, 01730 https://www.anikatherapeutics.com
IPO Date May 3, 1993
Employees 288
Officers Mr. Stephen D. Griffin Executive Vice President, Chief Financial Officer & Treasurer Dr. Cheryl Renee Blanchard Ph.D. President, Chief Executive Officer & Director Mr. David Colleran J.D. Executive Vice President, General Counsel & Corporate Secretary Mr. Ian W. McLeod Vice President & Chief Accounting Officer Ms. Anne Nunes Senior Vice President & Chief Operating Officer Ms. Lisa Funiciello Vice President of Human Resources Mr. James Chase Senior Vice President of International Sales & Marketing Mr. Ben Joseph Vice President of Commercial & Corporate Development Mr. Mark Namaroff Vice President of Investor Relations, ESG & Corporate Communications